Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure

Kidney International

Volumn 66, Issue 4, 2004, Pages 1578-1588

  Humes, H David ^a   Weitzel, William F ^b   Bartlett, Robert H ^b   Swaniker, Fresca C ^b   Paganini, Emil P ^b   Luderer, Jack R ^b   Sobota, Joseph ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Acute renal failure; Bioartificial kidney; Cell therapy; Stem cells; Systemic inflammatory response syndrome; Tissue engineering

Indexed keywords

CALCIFEDIOL; CALCITRIOL; CYTOKINE; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BIOARTIFICIAL ORGAN; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEVICE; EXTRACORPOREAL CIRCULATION; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HUMAN CELL; INTENSIVE CARE UNIT; KIDNEY TUBULE; KIDNEY TUBULE ASSIST DEVICE; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SAFETY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE ENGINEERING; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

EID: 4644247004     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00923.x     Document Type: Article

References (39)

1. HUMES HD: Cell therapy: Leveraging nature's therapeutic potential. J Am Soc Nephrol 14:2211-2213, 2003
2. WATANABE FD, MULLON CJ, HEWITT WR, et al: Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 225:484-491, 1997
3. MAKI T, OTSU I, O'NEIL JJ, et al: Treatment of diabetes by xenogeneic islets without immunosuppression. Use of a vascularized bioartificial pancreas. Diabetes 45:342-347, 1996
4. HUMES HD, BUFFINGTON DA, MACKAY SM, et al: Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 17:451-455, 1999
5. MEHTA RL: Therapeutic alternatives to renal replacement for critically ill patients in acute renal failure. Semin Nephrol 14:64-82, 1994
6. UNITED STATES RENAL DATA SYSTEM: Annual Data Report. Am J Kidney Dis 32(Suppl):569-580, 1998
7. HUMES HD: Bioartificial kidney for full renal replacement therapy. Semin Nephol 20:71-82, 2000
8. CHERTOW GM, LEVY EM, HAMMERMEISTER KE, et al: Independent association between acute renal and mortality following cardiac surgery. Am J Med 104:343-348, 1998
9. BATES DW, SU L, YU DT, et al: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-693, 2001
10. MEHTA RL, CHERTOW GM: Acute renal failure definitions and classification: Time for change? J Am Soc Nephrol 14:2178-2187, 2003
11. BREEN D, BIHARI D: Acute renal failure as a part of multiple organ failure: The slippery slope of critical illness. Kidney Int 53(Suppl 66):S25-S33, 1998
12. THAKAR CV, YARED JP, WORLEY S, et al: Renal dysfunction and serious infections after open-heart surgery. Kidney Int 64:239-246, 2003
13. BISHOP GA, WAUGH JA, HALL BM: Expression of HLA antigens on renal tubular cell stimulation of lymphocyte activation and on their vulnerability to cell-mediated lysis. Transplantation 46:303-310, 1988
14. WUTHRICH RP, YUI MA, MAZOUJIAN G, et al: Enhanced MHC class II expression in renal proximal tubules preceded loss of renal function in MRL//pr mice with lupus nephritis. Am J Pathol 134:45-51, 1989
15. WUTHRICH RP, GLIMCHER LH, YUR MA, et al: Generation of highly differentiated murine renal tubular epithelial cell lines: MHC class II regulation, antigen presentation and tumor necrosis factor production. Kidney Int 37:783-792, 1990
16. WAHL P, SCHOOP R, BILIC G, et al: Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 13:1517-1526, 2002
17. BOSWELL RN, YARD BA, SCHRAMA E, et al: Interleukin 6 production by human proximal tubular epithelial cells in vitro: Analysis of the effects of interleukin-1 alpha (IL-1 alpha) and other cytokines. Nephrol Dial Transplant 9:599-606, 1994
18. LEONARD M, RYAN MP, WATSON AJ, et al: Role of MAP kinase pathway in mediating IL-6 production in human primary mesangial and proximal tubular cells. Kidney Int 56:1366-1377, 1999
19. YARD BA, DAHA MR, KOOYMANS-COUTHINO M, et al: IL-1 alpha stimulated TNF alpha production by cultured human proximal tubular epithelial cells. Kidney Int 42:383-389, 1992
20. VAN KOOTEN C, VAN DER LINDE X, WOLTMAN AM, et al: Synergistic effect of interleukin-1 and CD40L on the activation of human renal tubular epithelial cells. Kidney Int 56:41-51, 1999
21. PRODJOSUDJADI W, GERRITSMA JS, KLAR-MOHAMED N, et al: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48:1477-1486, 1995
22. HUMES HD, MACKAY SM, FUNKE AJ, et al: Tissue engineering of a bioartificial renal tubule assist device: In vitro transport and metabolic characteristics. Kidney Int 55:2502-2514, 1999
23. FISSELL WH, DYKE DB, WEITZEL WF, et al: Bioartificial kidney alters cytokine response and hemodynamics in endotoxin challenged dogs. Blood Purif 20:55-60, 2002
24. FISSELL WH, LOU L, ABRISHAMI S, et al: Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 14:454-461, 2003
25. HUMES HD, FISSELL WH, WEITZEL WF, et al: Metabolic replacement of renal function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis 39(5):1078-1087, 2002
26. 2 concentration in accessible structures of the rat renal cortex. J Clin Invest 64: 476-482, 1979
27. CURTHOYS NP: Role of γ-glutamyltranspeptidase in the renal metabolism of glutathione. Miner Electrolyte Metab 9:236-245, 1983
28. SCOTT RD, CURTHOYS NP: Renal clearance of glutathione measured in rats pretreated with inhibitors of glutathione metabolism. Am J Physiol 252:F877-F882, 1987
29. FRASER DR, KODICEK E: Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228:764-766, 1970
30. DE VRIESE A, VANHOLDEN R, DE SUTTER J, et al: Continuous renal replacement therapies in sepsis: Where are the data? Nephrol Dial Transplant 13:1362-1364, 1998
31. SCHETZ M: Non-renal indications for continuous renal replacement therapy. Kidney Int 56:S88-S94, 1999
32. BONE RC: Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome and the multiple organ dysfunction syndrome. Ann Intern Med 125:680-687, 1996
33. BONE RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 24:163-172, 1996
34. HENDERSON B, POOLE S, WILSON M: Bacteria-Cytokine Interactions in Health and Disease, London, Portland Press, 1998
35. KNAUS WA, WAGNER DP, DRAPER EA, et al: The APACHE III prognostic system: Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100:1619-1636, 1991
36. HUMUS HD, BUFFINGTON DA, LOU L, et al: Cell therapy with a tissue-engineered kidney protects against the multi-organ consequences of septic shock. Crit Care Med 31:2421-2428, 2003
37. PINSKY MR, VINCENT JL, DEVIERE J, et al: Serum cytokine levels in human septic shock. Chest 103:565-575, 1993
38. HUMUS HD, WEITZEL WF, BARTLETT RH, et al: Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure. Blood Purif 21:64-71, 2003
39. PAGANINI EP, HALSTENBERG WK, GOORMASTIC M: Risk modeling in acute renal failure requiring dialysis: The introduction of a new model. Clin Nephrol 46:206-211, 1996